Navigation Links
Senesco's Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on 'Molecular Targets and Cancer Therapeutics'
Date:10/20/2008

tnered with leading-edge companies engaged in agricultural biotechnology and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the success of the Company's license agreements; the acceptance by the market of the Company's products; success of the Company's preliminary studies and preclinical research; competition and the timing of projects and trends in future operating performance, our ability to maintain our continued listing standards for the next 12 months, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Company Contacts: Investor Relations Contact:

Senesco Technologies, Inc. FD

Bruce Galton Brian Ritchie

Chief Executive Officer (brian.ritchie@fd.com)

(bgalton@senesco.com) (212) 850-5600

(732) 296-8400


'/>"/>
SOURCE Senesco Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Genmab Announces Encouraging Preclinical Data for ofatumumab
2. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
3. Preclinical Research on Coronary Stent with CeloNova BioSciences Polyzene(R)- F Nanocoating Receives Award at CIRSE 2007
4. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
5. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
6. Arpida Presents Preclinical Data on AR-2474 at ICAAC
7. ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference
8. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
9. ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests
10. Preclinical Efficacy Data Demonstrate Ability of Tengions Neo-Bladder Augment to Restore Bladder Function
11. GelVac(TM) Nasal Powder H5N1 (Bird Flu) Influenza Vaccine Passes Preclinical Toxicology Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... SAN JOSE, California , January 15, 2014 ... conjugates for cancer, today announced the appointment of Thomas C ... has over 20 years, development experience gained in the biotechnology ... "I am delighted to welcome Tom at this ...
(Date:1/15/2014)... , January 15, 2014 A study has ... on the Formula 1 track could help to tackle the ... Technologies (MAT), Stowhealth (a GP surgery based in Stowmarket) and ... provider Simplyhealth. Telemetry technology, which is inspired by ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent ... viruses is the Epstein Barr Virus (EBV), and one of ... a chronic inflammatory disease that destroys the body’s joints. As ... have high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... 2014 Freeslate, Inc ., the ... that Lupin Limited, one of India’s top five pharmaceutical ... PharmD System for high throughput solid form screening. ... on a wide range of quality, affordable generic and ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... do Dr. Peper, Dr. Sigmund Freud and Arnold Schwarzenegger ... be surprised to learn that Europeans love Dr. Peper. ... Erik Peper, President of the Biofeedback Foundation of Europe ... Dr. Erik Peper opens the 13th Annual Conference of ...
... Presents on Therapy Development StrategyCAMBRIDGE, Mass., Feb. 17 ... has announced the 2009 launch of its popular ... seminar is designed to inform and update patients, ... to discover and develop effective treatments for amyotrophic ...
... Inc. (OTC Bulletin Board: GNPH) ("Genesis" or the,"Company"), a ... Republic of China, today announced its financial results for ... 31, 2008. , , Second Quarter ... Revenue was $32.9 million, up 24.1% from the corresponding ...
Cached Biology Technology:Dr. Peper, Dr. Freud and Arnold Schwarzenegger 2Seminar Will Bring ALS Researchers to Patient Groups 2Seminar Will Bring ALS Researchers to Patient Groups 3Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 2Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 3Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 4Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 5Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 6Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 7Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 8Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 9Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 10Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 11Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 12Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 13Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 14Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 15Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 16
(Date:4/17/2014)... April 17, 2014The development of stem cell therapies to ... to characterize stem cell populations based on cell surface ... a new marker that is highly expressed in a ... blood, which they describe in an article in ... Ann Liebert, Inc., publishers. The article is available free ...
(Date:4/17/2014)... Marc Andr Gauthier and Professor Luca Razzari of ... been awarded large grants from the John R. ... Innovation (CFI) for the acquisition of state-of-the-art biotech ... added matching grants from the Ministre de l,Enseignement ... de la Technologie (MESRST). These new laboratories will ...
(Date:4/17/2014)... news release is available in German . ... us to recognise objects; they also provide us with a ... run, turn around, fall or sit still in a car ... motion trace on our retinas. Seemingly without effort, our brain ... maintain a stable position and a steady gaze during our ...
Breaking Biology News(10 mins):New state-of-the-art biotech and nanotech equipment for INRS 2How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4
... NARRAGANSETT, RI -- June 7, 2011 -- Sunshine Menezes, executive ... and 2010 Grantham Prize winner Alanna Mitchell announced the 2011 ... the Environment. James Astill of The Economist will receive US$75,000 ... a commanding 8-part special report on the state of global ...
... in billionths of a meter, self-assembling nano-sized devices designed ... are revolutionizing medicine by improving drug solubility and bio-distribution, ... and enabling membrane barriers to be crossed as well ... Self-assembling nano devices are now enlisted in the ...
... turns out, humans aren,t the only organisms that turn to ... four different bacteria that actually can live on caffeine. ... was found in a flowerbed outside a UI research laboratory. ... understanding of how the process works -- could in the ...
Cached Biology News:$75,000 Grantham Prize winner announced 2$75,000 Grantham Prize winner announced 3Super-mini vehicles carry therapeutics and imaging agents into body with mega results 2University of Iowa researchers identify caffeine-consuming bacterium 2
DryStrip aligners, 4. Category: Electrophoresis Systems & Standards & Reagents, IEF & SDS-PAGE & 2-D Electrophoresis, Multiphor II Kits & Components and Accessories....
...
...
Antibodies were affinity purified using epitopes specific to QKI immobilized on solid support....
Biology Products: